This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Muller, C. A. Articles by Peisach, M. Search for Related Content PubMed PubMed Citation Articles by Muller, C. A. Articles by Peisach, M.

Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia

maintenance of ventricular fibrillation threshold without inotropic compromise

^a Medical Research Council Heart Research Group, Cape Heart Centre, University of Cape Town, Cape Town, South Africa
^* National Accelerator Centre, Cape Town, South Africa

View larger version (43K): [in a new window]   Figure 1 Regional left ventricular blood flow. During ischemia, low dose mibefradil increased blood flow in the nonischemic (N I) zone. During reperfusion, low dose mibefradil caused increases in blood flow in both the ischemic (ISCH) and nonischemic zones, whereas verapamil increased blood flow only in the nonischemic zone (blood flow was not measured with higher dose of mibefradil). *p < 0.05, p < 0.01, both versus placebo. p < 0.01 versus verapamil.